Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
07 September 2021 | Story Leonie Bolleurs
Two lecturers in the Department of Computer Science and Informatics at the University of the Free State (UFS) authored and presented a paper that received the best paper award at this year’s 50th Annual Conference of the Southern African Computer Lecturers’ Association (SACLA). 

SACLA is an association for academics teaching Computer Science, Information Systems, and Information Technology subjects at universities and other higher education institutions in Southern Africa. The Academy of Computer Science and Software Engineering at the University of Johannesburg hosted the conference.

Dr Pakiso Khomokhoana, Lecturer in the Department of Computer Science and Informatics, presented the paper titled Mapping the problem-solving strategies of novice programmers to Polya's framework: SWOT analysis as a bottleneck identification tool. He chose this topic because he was concerned that students (especially novices) are always encountering challenges when it comes to understanding source code and working with related problems.

Prof Liezel Nel, Associate Professor in the Department of Computer Science and Informatics, co-authored the paper with Dr Khomokhoana.

“When the time came to announce the best paper, my heart was panting, and I was thrilled to hear elements of my paper mentioned in preparation for the final announcement,” says Dr Khomokhoana, who reckons that the amount of work one puts into a paper is equivalent to the yield you receive in return.

He is convinced that one should feel the ‘pinch’ for whatever you do in life. Those who are studying can relate to nights spent toiling, headaches, and stressed muscles, with the pain only going away after reaching your goal. “One has to work hard in order to succeed in life,” he states.

He says that being recognised for this paper not only means that he can produce more acceptable research in the future; with the feedback received from reviewers, he can help other upcoming researchers by imparting to them the research skills he obtained over the years.

The UFS also presented a second paper at the conference. Mokotsolane Mase, Lecturer from the same department on the UFS Qwaqwa Campus, presented a paper co-authored by Prof Nel as well, titled: Common code writing errors made by novice programmers: Implications for the teaching of Introductory Programming.

Continuous excellence

The SACLA programme committee is committed to keeping papers earmarked for journal publication to a very high standard. “Since only the top papers are earmarked for journal publication, it was a great achievement to have both papers selected for inclusion in the 2021 publication,” says Prof Nel. 

However, the highlight of the conference for her was when the paper she co-authored with Dr Khomokhoana was recognised as the best paper. 

“What makes this achievement even more special, is that it is the second time in three years that Dr Khomokhoana and I have received this award (2019 and 2021). This is also the third time (since the inception of the ‘best paper award’ in 2014) that I have been the co-author of the best paper.”

“Being recognised at this level for our research in the field of Computer Science Education (CSE) is testament to the quality and importance of the research being conducted within the CSE research group of the UFS Department of Computer Science and Informatics,” she says. 

The way forward

Prof Nel believes in the potential of the CSE research group, and her goal for the next five years is to continue to expand the CSE research group within the department. 

“What I love most about this type of research is that it requires a close integration of the lecturing and research roles of academics. As educational researchers, we must reflect critically on our current teaching and learning practices and consider ways in which we can ultimately provide our students with the best possible learning experiences that will adequately prepare them for the world of work. Mentoring young academics who are interested in this field of research, is one of my biggest passions. By sharing our research at conferences (such as SACLA) and through publication in international journals, we contribute to the scholarship of teaching and learning on a much broader scale,” she says. 

Dr Pakiso Khomokhoana reckons that the amount of work you put into a project is equivalent to the yield you receive in return.
Dr Pakiso Khomokhoana reckons that the amount of work you put into a project is equivalent to the yield you receive in return.
Prof Liezel Nel believes that educational researchers need to reflect critically on their current teaching and learning practices and consider ways in which to ultimately provide students with the best possible learning experiences.
Prof Liezel Nel believes that educational researchers need to reflect critically on their current teaching and learning practices and consider ways in which to ultimately provide students with the best possible learning experiences.
Mokotsolane Mase, lecturer from the same department on the UFS Qwaqwa Campus.
Mokotsolane Mase, lecturer from the same department on the UFS Qwaqwa Campus.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept